Oral Mucosal Tolerance Versus Systemic Immune Response to Salmonella typhi Antigen
American Journal of Biomedical and Life Sciences
Volume 3, Issue 4-1, July 2015, Pages: 13-16
Received: Mar. 17, 2015; Accepted: Mar. 28, 2015; Published: Apr. 23, 2015
Views 4132      Downloads 139
Ibrahim Mohamed Saeed Shnawa, College of Biotechnology, Al-Kasim University, Babylon Province, Iraq
Zainab Khudhur Ahmed Al-Mahdi, Medical Science Department, College of Nursing, Babylon University, Babylon Province, Iraq
Article Tools
Follow on us
It was demonstrated that the oral vaccine application of Salmonella typhi antigen can activate low antibody agglutinin titer (mean:40±0) comparing with high agglutination titer induced by Intramuscular administration of Salmonella typhi antigen (mean 560.0 ± 51.64) as well as anti-Salmonella typhi IgG ELIZA shows high mean index value(mean = 0.6957±0.10) comparing with the low index value induced by oral rout were (mean= 0.028±0.014) while anti Salmonella typhi IgM ELIZA test show mean index value = 0.6339±0.0385 comparing with low IgM index value (mean= 0.1560±0.070) induced by oral rout (Rsquared 0.7457, t test 3.3. The pro –inflammatory cytokines IL-1α was high in intramuscular rout 217.089±39.78 than its concentration with in oral administrated group (100.4±12.09), IL-12 was about the same concentration both in oral rout and intramuscular rout subsequently (23.607 and 23.17) p value 0.01, R squared (0.3958).However the immune responses were not absolutely absent in the oral administrated group, this reflect the fact that there is a selectivity in taking oral antigens from digestive mucosal surfaces but this immune feature and selectivity theme may vary from antigen to another. In conclusion the recent and ongoing expansion of a new information about the mucosal and systemic immune responses lend a promise to provide the tools needed to exploit the full potential and development of both mucosal and intramuscular vaccines.
Oral Tolerance, Systemic Immune Response, Intramuscular Rout
To cite this article
Ibrahim Mohamed Saeed Shnawa, Zainab Khudhur Ahmed Al-Mahdi, Oral Mucosal Tolerance Versus Systemic Immune Response to Salmonella typhi Antigen, American Journal of Biomedical and Life Sciences. Special Issue: Advances in Oral Immunity. Vol. 3, No. 4-1, 2015, pp. 13-16. doi: 10.11648/j.ajbls.s.2015030401.15
Kaufmann, H, E,S; Rouse, B, T, Sacks, D.L. 2011. The Immune Response to Infection. ASM, USA. pp:105.
Neutra M R, Kraenebahl J – P,1996,Antigen uptake by M cell for effective mucosal response, In Kiyono H, Ogra PL, McGee J R, eds, Mucosal Vaccines, Academic Press,London,3-14.
Oleszewska W, Openshaw PJM ,2004,Mucosal VaccinesIn Kauffmann ed, Novel Vaccine Strategies,Wiley,VCH,Verlag,GmbH&Co.,KGaA,Germany,343-359.
Staats H F, McGee JR1996 ,Principles of Mucosal Vaccination. In, Kiyono H, Ogra P L, McGee, J R, eds, Mucosal Vaccines, Academic Press, London, 15- 33.
Ogra P L ,1996,Mucosal Immunoprophlaxis: An introductory overview, In, Kiyono H, Ogra P L, McGee J R, eds, Mucosal Vaccines, Academic Press,London,3-14.
Ogra P L, Faden Hand Welliver R C.2001. Vaccination Strategies for Mucosal Immune Responses. ClinMicrobiol Rev. 2001 Apr; 14(2): 430–445.
Marth T, Strober W, Kelsall BL. 1996.High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis. J Immunol. 15;157(6):2348-57.
Willey J, Sherwood L, Woolverton C. 2008. Microbiology 7th ed. Prescott Harley &Kleins McGraw-Hill.
Svanborg E C, Kulhavy R, Marlid S, Prince S Jand Mestecky J.1985. Urinary immunoglobulins in healthy individuals and children with acute pyelonephritis. Scand .J. Immunol.,305-313.
Steven C D. 2010. Clinical Immunology and Serology: A Laboratory Perspective,3edFA Davis Company, Philadelphia.
Marie-Christiane M, Valerie G R. 2001. Influence of Resident Intestinal Micro oral on the Development and Functions of the Gut-Associated Lymphoid Tissue. Microbial Ecology in Health and Disease. 13: 65–86.
Herman F. Staats and Francis A. Ennis, Jr. 1999. IL-1 Is an Effective Adjuvant for Mucosal and Systemic Immune Responses When Coadministered with Protein Immunogens1, Herman F. Staats2 and Francis A. Ennis, Jr. The Journal of Immunology. 162: 6141–6147.
Weiner HL. 2001. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect. 3(11):947-54.
Jiri M, Zina M, Charles O E. 2005. Immune response versus mucosal tolerance to mucosally administered antigens. J. Vaccine 23:1800–1803.
-Barone K S, Tolarova D D, Ormsby I, Doetschman T, Michael J G. 1998. Induction of oral tolerance in TGF-β1 null mice. J Immunol. 161:154–160.
Mowat A M, Weiner H L. Oral tolerance: physiological basis and clinical applications.1999. In: Ogra P L, Mestecky J, Lamm M E, Strober W, Bienenstock J, McGhee J R, editors. Mucosal immunology. 2nd ed. New York, N.Y: Academic Press; pp. 587–618.
Mason KL, Huffnagle GB, Noverr MC, Kao JY. 2008. Overview of gut immunology. AdvExp Med Biol. 2008; 635:1-14. doi: 10.1007/978-0-387-09550-9_1.
Jasvir S J, Mark J P ,Suman G, Laura K. Phillip W. Marry E B, and Steven D L, Lucill L. 2012. Salivary glands act as mucosal inductive sites via the formation of ectopic germinal centers after site-restricted MCMV infection. J.FASEB, 25(5): 1680-1696.
Weigle W O, 1998, Immune Tolerance Model, In.Delves P J and Roitt I M ed. Encyclopedia of Immunology 2d ed , Vol.4, Academic Press, New York, 2359-2361.
Jiang X, Nicolls M R, 2014, Working towards immune tolerance in lung transplantation, J. Clin. Invest., 124(3)967-970.
Kubn C, You S, Valette F, Endert P V, Bach J-F, Waldmann H, Chatenoud L. 2011, Human CD3 transgenic mice: Preclinical testing of antibodies promoting immunological tolerance, Translat. Med, 3(68):678-78.
Shnawa IMS. 2015. Oral mucosal immune tolerance versus oral immune silenceing: Minireview, Am. J. Biomed. Lif. Sci. 3(4-1)7-9.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186